Trials / Not Yet Recruiting
Not Yet RecruitingNCT07229612
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
A Multicenter, Open-label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4298 Injection in Patients With Malignant Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-4298 injection in patients with malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-4298 Injection | SHR-4298 injection. |
Timeline
- Start date
- 2025-11-01
- Primary completion
- 2028-11-01
- Completion
- 2028-11-01
- First posted
- 2025-11-17
- Last updated
- 2025-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07229612. Inclusion in this directory is not an endorsement.